COSMOS Pharmaceutical Gross Profit

The latest gross profit for CSMYF is $230B as of August 2026. That compares with $220B in the prior-year period — up 8.7% year over year. That is below the sector sector average of $6T. Investors often review this figure alongside COSMOS Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSMYF's gross profit moved from $220B to $230B — a 8.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in COSMOS Pharmaceutical's operating scale or balance-sheet position.

Against its sector companies, CSMYF currently prints $230B for gross profit, while the sector average sits near $6T. That is roughly 96.1% below the sector mean. Large gaps often invite a closer look at COSMOS Pharmaceutical's growth, margins, and balance sheet.

A gross profit figure of $230B for CSMYF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $6T. Explore the charts below for those layers of context.

After noting CSMYF's gross profit ($230B), review year-over-year change from $220B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.